Patents by Inventor Orn Almarsson

Orn Almarsson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10258698
    Abstract: The present disclosure provides, inter alia, formulation compositions comprising modified nucleic acid molecules which may encode a protein, a protein precursor, or a partially or fully processed form of the protein or a protein precursor. The formulation composition may further include a modified nucleic acid molecule and a delivery agent. The present invention further provides nucleic acids useful for encoding polypeptides capable of modulating a cell's function and/or activity.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: April 16, 2019
    Assignee: ModernaTX, Inc.
    Inventors: Stephen G. Hoge, Örn Almarsson, David D. Hile, Ciarán Lawlor, John Podobinski, Staci Sabnis, Antonin de Fougerolles, Divakar Ramakrishnan, Kristy M. Wood
  • Publication number: 20190031648
    Abstract: The invention provides a method of sustained delivery of a lactam, imide, amide, sulfonamide, carbamate or urea containing parent drug by administering to a patient an effective amount of a prodrug compound of the invention wherein upon administration to the patient, release of the parent drug from the prodrug is sustained release. Prodrug compounds suitable for use in the methods of the invention are labile conjugates of parent drugs that are derivatized through carbonyl linked prodrug moieties. The prodrug compounds of the invention can be used to treat any condition for which the lactam, imide, amide, sulfonamide, carbamate or urea containing parent drug is useful as a treatment.
    Type: Application
    Filed: June 29, 2018
    Publication date: January 31, 2019
    Inventors: Laura Cook Blumberg, Julius F. Remenar, Orn Almarsson, Tarek A. Zeidan
  • Patent number: 10040787
    Abstract: The invention provides a method of sustained delivery of a lactam, imide, amide, sulfonamide, carbamate or urea containing parent drug by administering to a patient an effective amount of a prodrug compound of the invention wherein upon administration to the patient, release of the parent drug from the prodrug is sustained release. Prodrug compounds suitable for use in the methods of the invention are labile conjugates of parent drugs that are derivatized through carbonyl linked prodrug moieties. The prodrug compounds of the invention can be used to treat any condition for which the lactam, imide, amide, sulfonamide, carbamate or urea containing parent drug is useful as a treatment.
    Type: Grant
    Filed: August 3, 2016
    Date of Patent: August 7, 2018
    Assignee: ALKERMES PHARMA IRELAND LIMITED
    Inventors: Laura Cook Blumberg, Julius F. Remenar, Orn Almarsson, Tarek A. Zeidan
  • Publication number: 20180214579
    Abstract: The present invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides formulations containing amino acids.
    Type: Application
    Filed: March 26, 2018
    Publication date: August 2, 2018
    Inventors: Örn ALMARSSON, Noubar B. AFEYAN, Joseph Beene BOLEN, Staci SABNIS
  • Publication number: 20180085474
    Abstract: Disclosed herein are nanoparticle compositions including an mRNA and a lipid component and methods of using the same.
    Type: Application
    Filed: January 21, 2016
    Publication date: March 29, 2018
    Inventors: Orn ALMARSSON, Ciaran LAWLOR
  • Patent number: 9925277
    Abstract: The present invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides formulations containing amino acids.
    Type: Grant
    Filed: September 12, 2014
    Date of Patent: March 27, 2018
    Assignee: ModernaTX, Inc.
    Inventors: Örn Almarsson, Noubar B. Afeyan, Joseph Beene Bolen, Staci Sabnis
  • Publication number: 20180000953
    Abstract: Disclosed herein are nanoparticle compositions including an mRNA and a lipid component and methods of using the same. The present invention provides compositions and methods involving lipid-containing nanoparticle compositions to deliver mRNA to cells. In one aspect, the invention provides a nanoparticle composition including (i) a lipid component including a phospholipid (which may or may not be unsaturated), a PEG lipid, a structural lipid, and a compound of formula (I) and (ii) an mRNA encoding a polypeptide of interest.
    Type: Application
    Filed: January 21, 2016
    Publication date: January 4, 2018
    Inventors: Orn ALMARSSON, Ciaran Patrick LAWLOR
  • Publication number: 20170196848
    Abstract: The invention provides a method of sustained delivery of a lactam, imide, amide, sulfonamide, carbamate or urea containing parent drug by administering to a patient an effective amount of a prodrug compound of the invention wherein upon administration to the patient, release of the parent drug from the prodrug is sustained release. Prodrug compounds suitable for use in the methods of the invention are labile conjugates of parent drugs that are derivatized through carbonyl linked prodrug moieties. The prodrug compounds of the invention can be used to treat any condition for which the lactam, imide, amide, sulfonamide, carbamate or urea containing parent drug is useful as a treatment.
    Type: Application
    Filed: January 23, 2017
    Publication date: July 13, 2017
    Inventors: Laura Cook Blumberg, Julius F. Remenar, Orn Almarsson, Tarek A. Zeidan
  • Patent number: 9670200
    Abstract: The invention provides a method of sustained delivery of a tertiary amine-containing parent drug comprising administering to a patient an effective amount of a prodrug compound of the invention wherein upon administration to the patient, release of the parent drug from the prodrug is sustained release. Prodrug compounds suitable for use in the methods of the invention are labile quaternary ammonium salts of tertiary amine-containing parent drugs (or tertiary imine-containing parent drugs) that are derivatized through aldehyde-linked prodrug moieties that reduce the solubility of the prodrug compound at a reference pH as compared to the parent drug. The physical, chemical and solubility properties of these derivatives can be further modulated by the choice of counterion X?. In one embodiment, the present invention provides a prodrug compound of Formula I: where R1-R5 are defined in the written description of the invention.
    Type: Grant
    Filed: December 23, 2010
    Date of Patent: June 6, 2017
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: Örn Almarsson, Laura Cook Blumberg, Julius F. Remenar
  • Patent number: 9585965
    Abstract: The invention provides a method of sustained delivery of a lactam, imide, amide, sulfonamide, carbamate or urea containing parent drug by administering to a patient an effective amount of a prodrug compound of the invention wherein upon administration to the patient, release of the parent drug from the prodrug is sustained release. Prodrug compounds suitable for use in the methods of the invention are labile conjugates of parent drugs that are derivatized through carbonyl linked prodrug moieties. The prodrug compounds of the invention can be used to treat any condition for which the lactam, imide, amide, sulfonamide, carbamate or urea containing parent drug is useful as a treatment.
    Type: Grant
    Filed: May 22, 2015
    Date of Patent: March 7, 2017
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: Laura Cook Blumberg, Julius F. Remenar, Orn Almarsson, Tarek A. Zeidan
  • Patent number: 9580417
    Abstract: The present invention relates to prodrugs of parent drug compounds containing heteroaromatic NH groups.
    Type: Grant
    Filed: July 13, 2015
    Date of Patent: February 28, 2017
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: Laura Cook Blumberg, Orn Almarsson
  • Publication number: 20170015659
    Abstract: The invention provides a method of sustained delivery of a lactam, imide, amide, sulfonamide, carbamate or urea containing parent drug by administering to a patient an effective amount of a prodrug compound of the invention wherein upon administration to the patient, release of the parent drug from the prodrug is sustained release. Prodrug compounds suitable for use in the methods of the invention are labile conjugates of parent drugs that are derivatized through carbonyl linked prodrug moieties. The prodrug compounds of the invention can be used to treat any condition for which the lactam, imide, amide, sulfonamide, carbamate or urea containing parent drug is useful as a treatment.
    Type: Application
    Filed: August 3, 2016
    Publication date: January 19, 2017
    Inventors: Laura Cook Blumberg, Julius F. Remenar, Orn Almarsson, Tarek A. Zeidan
  • Publication number: 20160243259
    Abstract: The present invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides formulations containing amino acids.
    Type: Application
    Filed: September 12, 2014
    Publication date: August 25, 2016
    Inventors: Örn ALMARSSON, Noubar B. AFEYAN, Joseph Beene BOLEN, Staci SABNIS
  • Publication number: 20160009713
    Abstract: The present invention relates to prodrugs of parent drug compounds containing heteroaromatic NH groups.
    Type: Application
    Filed: July 13, 2015
    Publication date: January 14, 2016
    Inventors: Laura Cook Blumberg, Orn Almarsson
  • Publication number: 20150376143
    Abstract: The invention provides a method of sustained delivery of a lactam, imide, amide, sulfonamide, carbamate or urea containing parent drug by administering to a patient an effective amount of a prodrug compound of the invention wherein upon administration to the patient, release of the parent drug from the prodrug is sustained release. Prodrug compounds suitable for use in the methods of the invention are labile conjugates of parent drugs that are derivatized through carbonyl linked prodrug moieties. The prodrug compounds of the invention can be used to treat any condition for which the lactam, imide, amide, sulfonamide, carbamate or urea containing parent drug is useful as a treatment.
    Type: Application
    Filed: June 30, 2015
    Publication date: December 31, 2015
    Inventors: Laura Cook Blumberg, Julius F. Remenar, Orn Almarsson, Tarek A. Zeidan
  • Publication number: 20150320875
    Abstract: The invention provides a method of sustained delivery of a lactam, imide, amide, sulfonamide, carbamate or urea containing parent drug by administering to a patient an effective amount of a prodrug compound of the invention wherein upon administration to the patient, release of the parent drug from the prodrug is sustained release. Prodrug compounds suitable for use in the methods of the invention are labile conjugates of parent drugs that are derivatized through carbonyl linked prodrug moieties. The prodrug compounds of the invention can be used to treat any condition for which the lactam, imide, amide, sulfonamide, carbamate or urea containing parent drug is useful as a treatment.
    Type: Application
    Filed: May 22, 2015
    Publication date: November 12, 2015
    Inventors: Laura Cook Blumberg, Julius F. Remenar, Orn Almarsson, Tarek A. Zeidan
  • Patent number: 9107911
    Abstract: The present invention relates to prodrugs of parent drug compounds containing heteroaromatic NH groups.
    Type: Grant
    Filed: December 23, 2010
    Date of Patent: August 18, 2015
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: Laura Cook Blumberg, Örn Almarsson
  • Patent number: 9102618
    Abstract: The invention provides a method of sustained delivery of a lactam, imide, amide, sulfonamide, carbamate or urea containing parent drug by administering to a patient an effective amount of a prodrug compound of the invention wherein upon administration to the patient, release of the parent drug from the prodrug is sustained release. Prodrug compounds suitable for use in the methods of the invention are labile conjugates of parent drugs that are derivatized through carbonyl linked prodrug moieties. The prodrug compounds of the invention can be used to treat any condition for which the lactam, imide, amide, sulfonamide, carbamate or urea containing parent drug is useful as a treatment.
    Type: Grant
    Filed: February 4, 2014
    Date of Patent: August 11, 2015
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: Laura Cook Blumberg, Julius F. Remenar, Orn Almarsson, Tarek A. Zeidan
  • Publication number: 20150210712
    Abstract: The present invention relates to compounds of Formula I:
    Type: Application
    Filed: February 3, 2015
    Publication date: July 30, 2015
    Inventors: Laura Cook Blumberg, John A. Lowe, III, Orn Almarsson, Juan Alvarez, Tarek A. Zeidan
  • Patent number: 9072788
    Abstract: The invention provides a method of sustained delivery of a lactam, imide, amide, sulfonamide, carbamate or urea containing parent drug by administering to a patient an effective amount of a prodrug compound of the invention wherein upon administration to the patient, release of the parent drug from the prodrug is sustained release. Prodrug compounds suitable for use in the methods of the invention are labile conjugates of parent drugs that are derivatized through carbonyl linked prodrug moieties. The prodrug compounds of the invention can be used to treat any condition for which the lactam, imide, amide, sulfonamide, carbamate or urea containing parent drug is useful as a treatment.
    Type: Grant
    Filed: September 24, 2013
    Date of Patent: July 7, 2015
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: Laura Cook Blumberg, Julius F. Remenar, Orn Almarsson, Tarek A. Zeidan